Lemtrada Carries Serious Side Effects That Come With The Potential Relief The Drug Offers

RRMS patients are usually desperate and at the stage where they will try anything before engaging in dangerous Lemtrada treatments

Monday, June 1, 2020 - Lemtrada's maker Sanofi has told patients that the drug is highly effective in reducing the progression of relapse remitting multiple sclerosis (RRMS) and also in preventing relapses in patients. There is never a bad time, however, to review the potential adverse side effects that relapse RRMS drug Lemtrada can have on a patient. Health safety organizations in private and also in government have both issued the sternest possible warnings for patients and doctors alike to observe before starting the last-resort RRMS regimen. Lemtrada stroke lawsuit attorneys are offering a free no obligation, consultation before filing a lawsuit claim.

While some patients are desperate for any sign that their disease's symptoms could be alleviated even temporarily, Lemtrada can cause instant death on the spot during treatment. Not only that, but the European Union's Pharmacovigilance Risk Assessment Committee (PRAC) has also said that Lemtrada's side effects can affect a patient's vital organs up to a year after treatments. According to a report written in Multiple Sclerosis News Today: "reports of fatalities and severe effects were associated with immune complications that included autoimmune hepatitis (immune-caused liver damage) and hemophagocytic lymphohistiocytosis (a disorder that may affect several organs in the body), and hemolytic anemia (abnormal red cell breakdown). Some immune reactions could happen "many months" after treatment with Lemtrada, PRAC noted."

In addition to the autoimmune system complication and blood chemistry disorders, the latest study of Lemtrada found that the drug also causes life-threatening ANCA vasculitis. ANCA stands for "Anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis is an autoimmune disease that causes blood vessels to swell." When a person develops this condition from taking Lemtrada a type of white blood cell is rendered out of control and attacks neutrophil blood cells that break through the blood vessel walls trying to escape. There is an almost limitless number of adverse conditions that can occur when this happens depending on where the blood vessel breach occurs such as kidney damage. According to Ancavasculitis.com, "skin lesions and nerve damage depending on which areas are affected. Weight loss and fevers frequently occur as well."

Lemtrada is classified as a disease-modifying therapy (DMT) and should be taken as a last resort only when all other potential DMTs have been attempted and failed according to the European Medicines Agency's (EMA) drug safety committee. Lemtrada patients also must be monitored before, during, and after treatments for signs of "certain heart, circulation or bleeding disorders."

Despite the avalanche of negative health warning surrounding Lemtrada, patients continue to swear by the drug as it can help alleviate the symptoms of RRMS that patients are desperate to end at least temporarily. More than a few RRMS patients struggle with spasticity rendering independently walking progressively more difficult and eventually impossible. Patients tell that taking Lemtrada helped them to walk with the aid of a walking device and some even without one. RRMS also often begins with tingling in the hands that progresses up the arm, shoulder to the head, and neck make holding one's head still and upright becomes impossible and leaving the patient feeling severely uncomfortable. Lemtrada patients report the tingling disappearing and feeling much more comfortable overall.

More Recent Lemtrada Stroke Lawsuit News:

No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.